Call for Partners | G-FORCE: GLP-1, food-origin regulators and appetite control effects

Pharmacological GLP-1 agonists (e.g., Ozempic) are transforming obesity treatment. These drugs drive significant weight loss with metabolic health benefits. However, this shift raises critical questions and concerns, but it also unlocks new scientific and commercial opportunities.
Partner up for impact

Information
- May 1, 2026 - May 1, 2030
- Dutch Top sector AgriFood subsidy
- €1.5–2.0 million
- Ingredient suppliers and end-product manufacturers
- Developments in GLP-1 and satiation
About the project
Within G-force, we aim to identify natural ingredients that enhance endogenous GLP-1 release and to gain a deeper understanding of their mechanisms of action. Partners are invited to contribute ingredients of interest for testing. We will employ state-of-the-art in vitro cell assays, receptor assays, and in vivo human clinical trials.
Based on these findings we will assess the satiating potential of a selection of food items. Our ultimate goal is to develop effective dietary strategies to support appetite regulation and reduce the risk of overeating. In addition, we will investigate whether GLP-1 agonist administration leads to shifts in food preferences and sensory perception. This will be explored within an existing prospective cohort designed to monitor health outcomes of obesity treatment. By gaining insight into how pharmacological GLP-1 treatment influences food preferences, we aim to better understand and respond to the evolving needs of this rapidly growing consumer group.
Let's connect!
For more information about the project or to collaborate, please contact our expert.
D (Diederik) Esser, PhD
WR Onderzoeker
Follow Food and Biobased Research on social media
Stay up-to-date and learn more about our research through our social channels.